Equillium, Inc.

EQ Healthcare Biotechnology

Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023.

Revenue
−52.3%
EPS
+75.0%
Free cash flow
−38.7%

Quarter to June 2026, against a year earlier

1.34 0.06 −4.29%
Market cap
$84.3M
P/E
0.0×
Fwd P/E
−5.2×
Dividend yield
—
F-score
3/9
Altman Z
−6.76
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
10.85 10.58 18.62 23.40
Net Debt/EBITDA
7.28 7.69 10.98 11.15
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.13) (0.06) (0.04) (0.04)
Book value per Share
0.47 0.50 0.62 0.50
Free Cash Flow
(8.43) (3.16) (4.30) (4.18)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates